A simplified prognostic score is presented based on the multivariate analysis of 138 refractory/relapsed acute myeloid leukaemia (AML) patients (median age 55 years, range: 19-70) receiving a combination of intensive chemotherapy þ Gemtuzumab as salvage regimen. Overall, 2-year event-free survival (EFS) and overall survival (OS) were 29±4% and 36 ± 4%, respectively. Disease status (relapse o12 months, including refractory patients), FLT3-ITD-positive status and high-risk cytogenetics were the three strongest independent adverse prognostic factors for OS and EFS in this series. We then defined three subgroups with striking different outcomes at 2 years: no adverse factor (favourable, N ¼ 36): OS 58%, EFS 45%; one adverse factor (intermediate, N ¼ 54): OS 37%, EFS 31%; two or three adverse factors (poor, N ¼ 43): OS 12%, EFS 12% (Po10
Introduction
Relapsed or refractory acute myeloid leukaemia (AML) patients have still a very dismal outcome. [1] [2] [3] Patients who could proceed to an allogeneic transplantation, either after a sequential conditioning regimen in case of refractory disease 4 or after a standard or reduced intensity conditioning regimen in case of second complete remission (CR), 3, 5 are likely to have the best chances to achieve long-term overall survival (OS).
At present, there is no widely approved salvage regimen for refractory/relapsed AML. 6 However, we have recently shown that a chemo-immunotherapy combining Gemtuzumab Ozogamicin (GO), intermediate dose Ara-C and Mitoxantrone (MIDAM regimen) 7 represents a valid therapeutic option in this setting, allowing to achieve an overall response (OR) rate of 63%, and a disease-free and OS rates of 41 and 53%, respectively, at 2 years. Moreover, we have also shown that normal karyotype (NK) AML patients, receiving the MIDAM protocol and who had a favourable molecular profile (that is, mutated nucleophosmin gene (NPM1 þ ) without internal tandem duplications of the fms-like tyrosine kinase 3 gene (FLT3-ITDÀ)), retained a good prognosis compared with other subgroups with NK. 8 If well-known prognostic factors are identified for refractory/ relapsed AML outcomes such as age, performans status, karyotype, duration of first CR or previous stem cell transplant, 5 currently, there is no series having studied the prognostic impact of the new molecular parameters compared with others factors in this setting. The aim of this study was to define a predictive score integrating the new molecular parameters in the setting of refractory/relapsed AML patients in order to propose appropriate therapeutic strategies to these patients.
Patients and methods

Study design and patients selection criteria
This was a retrospective multicenter study which included 138 adult patients (female n ¼ 75; male n ¼ 63) with refractory (n ¼ 57) or relapsed (n ¼ 81) AML and treated in six institutions (Nantes, Limoges, Marseille, Bordeaux, Angers and Rehovot) in France and Israel, between 2001 and 2009. The patients were treated in different therapeutic trials or programs at the corresponding institution. Written informed consent was obtained from each patient. The studies were approved by the local ethical committee and performed according to institutional guidelines. No selection criteria other than 'relapsed/refractory AML treated with GO and intensive chemotherapy as salvage regimen' was used for the purpose of this analysis. The outcome of previously published patients [7] [8] [9] was updated as of March 2010. Patients o60 years of age with no CR after a double induction chemotherapy (including one with intermediate or high dose Ara-C), patients over 60 years of age with no CR after one induction chemotherapy and patients who relapsed within 6 months after CR were considered as refractory AML. 7 The median age in this cohort was 55 (range, 19-70) years old at time of AML diagnosis. All patients had CD33-positive blasts (median: 98% CD33 þ blasts). As salvage regimen, 128 patients received the previously published MIDAM regimen (GO: 9 mg/m 2 at day 4 þ Ara-C 1 g/m 2 /12 h at days 1-5 þ Mitoxantrone 12 mg/m 2 /day at days 1-3). 7 The remaining 10 patients received other intensive GO-based combinations (Ara-C, VP16 and GO: n ¼ 3; Ara-C, Idarubicine and GO: n ¼ 2; Ara-C, Amsacrine and GO: n ¼ 2; Ara-C and GO: n ¼ 3).
In this series, all but five patients could be screened at time of diagnosis in peripheral blood or bone marrow samples for internal tandem duplication in the FLT3 gene (FLT3-ITD) and mutation of the NPM1 gene as previously described. 10, 11 CEBPa mutations screening was not investigated in this study because of insufficient material. Cytogenetics data at diagnosis were available for all patients. Patients' characteristics are summarized in Table 1 .
To determine its impact in the setting of refractory/relapsed AML, patients from this cohort were also classified according to the new European Leukemia Net (ELN) prognosis subsets, proposed recently by an expert panel. 3 This standardized report for the correlation of cytogenetics and molecular data in AML patients at diagnosis integrates the favourable molecular profile 
Endpoints definition
CR was defined as normalization of peripheral blood counts (neutrophils 41 Â 10 9 /l and platelets 4100 Â 10 9 /l) and bone marrow with p5% blasts after salvage therapy, CR with incomplete platelets recovery (CRp) was defined like CR but with platelet transfusion independence and platelet counts remaining o100 Â 10 9 /l. CR þ CRp was defined as OR. All other types of responses were considered as failure. Survivals were calculated from the date of the documentation of relapse or refractory disease until death or to last follow-up for OS, or to failure, relapse, death or last follow-up for event-free survival (EFS).
Statistical analysis
Descriptive statistics are reported as frequencies, or medians and range. The w 2 test was used to test for factors associated with OR. OS and EFS were estimated by the Kaplan-Meier product limit method. The log-rank test was used for univariate comparisons. The following parameters were taken into account for analyses of prognostic factors for survivals: age, sex, FrenchAmerican-British classification (M5 M6 M7 vs others), type of AML (de novo or secondary), cytogenetics and molecular status, status at time of salvage regimen (relapsed or refractory AML), duration of CR1 for relapsed patients (46 months and p12 months; 412 months), previous stem cell transplantation, type of salvage regimen (MIDAM vs other). Associations of patient and disease characteristics with outcomes are evaluated in multivariate analyses, using Cox proportional hazards for OS, and logistic regression for response rate.
All factors associated with a P-value o0.20 by univariate analysis were forced in multivariate analyses, except the NPM1 molecular status as it was strictly associated with intermediate cytogenetics and French-American-British classification as it was also associated with cytogenetics (P ¼ 0.03). Adjusted hazard ratios (HRs) were calculated for each factor. Integer weights for the construction of the score were derived from Cox proportional hazards modeling with OS over the first 2 years as the outcome. Adjusted HRs were converted to integer weights according to the following: factors with adjusted HR of p1.4 were dropped from consideration, factors with adjusted HR of 1.5-2.0 were assigned a weight of 1. The score was the sum of these integer weights. Because of small numbers, the original score was reduced to three risk groups: 0 (low risk), 1 (intermediate risk) and 2-3 (high risk). The scores were applied to patients of the validation set to test their ability to predict for HR of 2-year survival.
The final analysis was performed as of end of July 2010 using SPSS Inc., 18.0 (Chicago, IL, USA). 
OR, EFS and OS
In this analysis, the median follow-up for the whole cohort was 18 months (range, Two-years EFS and OS were 29 ± 4% and 36 ± 4%, respectively. In univariate analysis, prognostic factors associated with a significantly improved EFS and OS are listed in Table 2 . Among 88 patients achieving CR þ CRp, 42 relapsed (47.7%) during follow-up. At last follow-up, 94 patients (68%) died with leukaemia being the cause of death in 70 cases. The other causes of deaths included sepsis (n ¼ 8), graft-versus-host disease (acute n ¼ 1; chronic n ¼ 4), veno-occlusive disease (n ¼ 5), multiple organ failure (n ¼ 2), haemorrhage (n ¼ 3) or secondary malignancy (n ¼ 1; renal carcinoma). Considering the 94 patients who died, 10 have died early after the salvage regimen because of toxicity (veno-occlusive disease n ¼ 5; haemorrhage n ¼ 2; sepsis n ¼ 2 and multiple organ failure n ¼ 1).
After salvage therapy, 47 patients underwent an allogeneic stem cell transplant (myeloablative conditioning: n ¼ 1; reduced intensity conditioning regimen: n ¼ 46). The majority of patients Prognostic score for refractory/relapsed AML P Chevallier et al (n ¼ 40) received the allo-transplant because they achieved CR after the salvage treatment while seven unresponsive patients received the allo-transplant because of the availability of a human leukocyte antigen-matched identical donor and good performans status without major comorbidities. The 2-year OS for these patients was 45±9%.
Prognostic score for relapsed/refractory adult AML patients
The aim of this study was to develop a predictive scoring system in the setting of refractory/relapsed AML patients integrating new molecular prognostic parameters. Thus, we applied multiple multivariate Cox regression analyses to detect independent prognostic factors for OS. Finally, three independent prognostic factors were significantly associated with higher OS (Table 3) : the molecular status (FLT3-ITDÀ vs þ ), cytogenetics (favourable and intermediate vs poor) and the disease status (relapse 412 months vs relapse between 6 and 12 months and refractory patients). Three prognostic groups (favourable (0 adverse prognostic factor), intermediate (1 adverse prognostic factor) and poor (2 or 3 adverse prognostic factors)) could then be identified for OS as described in Table 4 . OS and EFS curves according to the three subgroups are shown in Figures 1 and 2 .
Given the striking differences obtained when using the above scoring system, we thought to test its validity on an independent cohort of 111 refractory/relapsed AML patients initially included in the prospective GOELAMS LAM-2001 trial 12, 13 as first-line therapy. Status disease (refractory, relapse between 6 and 12 months and relapse 412 months), cytogenetics and molecular status were available for all 111 patients. Patients from this prospective GOELAMS LAM-2001 trial received various intensive chemotherapies as salvage regimen.
The HR and 2-year OS are summarized by scores for the training and validation sets in Table 5 .
Discussion
This is the first large series reporting on the outcome of refractory/relapsed AML patients taking into account, beside well-recognized prognostic factors, such as cytogenetics, disease status or duration of first CR, the new molecular parameters, that is, NPM1 mutation and FLT3-ITD. We confirm here that patients with NK and favourable molecular status have a very good prognosis, 8 sharing similar EFS and OS compared with patients with favourable cytogenetics. These results are in favour of the fusion of this two subgroups in a same entity of good prognosis in the setting of refractory/relapsed AML, Table 3 Multivariate analyses for overall survival Prognostic score for refractory/relapsed AML P Chevallier et al as recommended already at diagnosis by the new prognostic classification proposed recently by an international expert panel. 3 Also, we were able to demonstrate for the first time, in this setting, that FLT3-ITD was indeed associated with adverse EFS and OS. The negative impact of FLT3-ITD has previously been demonstrated on first-line therapy. 3 Following the ELN classification, patients in the intermediate-1 subgroup, where FLT3-ITD þ cases were concentrated (86% of FLT3-ITD þ patients in this series) shared similar outcomes compared with patients classified in the adverse group, demonstrating the strong negative impact of FLT3-ITD. Thus, if, as documented here, the new ELN classification kept its prognostic significance in the setting of refractory/relapsed AML, in term of EFS and OS, there might be a need to improve this prognosis index regarding to FLT3-ITD.
We were then interested by the elaboration of a new prognostic score integrating the new molecular parameters. As NPM1 þ status was strictly associated with intermediate cytogenetic, we made the choice to not consider this marker in multivariate analyses. Thus, the independent variables with the highest impact on OS were the cytogenetic (combining patients with favourable and intermediate cytogenetic because of similar outcomes vs high risk), the duration of first CR (combining refractory patients þ patients in relapse between 6 and 12 months because of similar outcomes vs patients in relapse 412 months) and still the FLT3-ITD status. The two first parameters can be easily documented, but investigation of the FLT3-ITD status is usually performed only in patients with NK. This study pleads towards analysing FLT3-ITD in all AML patients at diagnosis or relapse, especially those with favourable cytogenetics. Because of the characterization of these three strong prognostic factors for OS, we were able to establish a new simplified prognostic score for refractory/relapsed AML patients, dubbed the Leukemia Progression Scoring System. Currently, and as recommended by the international expert panel, 3 the score of Breems et al, 5 including four parameters (length of relapse-free interval after CR1, cytogenetics at diagnosis, age at relapse and previous stem cell transplantation), validated by Giles et al, 14 should be considered for all studies with relapsed AML. Nevertheless, this study published in 2005 has several limitations regarding new recent advances in the setting AML. For example, it did not include patients 460 years old, or with refractory disease and especially new molecular parameters. Also, our score was validated on an independent cohort of patients receiving chemotherapy as salvage regimen, demonstrating the pertinence of the Leukemia Progression Scoring System. This is of crucial importance as the US Food and Drug Administration has recently announced the withdrawal of the GO because of concerns about the product's safety and the clinical benefit to patients enrolled in trials. Although we are still convinced, with others, 15, 16 that GO may have some interest in particular subgroups of AML patients, it seems that our new prognostic method for refractory/relapsed AML is broadly applicable to all intensive regimens, whether or not they contain GO.
Finally, it seems that the new prognostic score proposed here could be more adapted to predict outcome and tailor therapeutic strategies. Thus, patients in the favourable/intermediate groups (0 or 1 adverse prognostic factor) should be considered for an intensive salvage regimen followed by an allogeneic transplantation in case of available donor, while patients in the adverse group (2 or 3 adverse prognostic factors) should be considered for investigational therapies, for example an anti-FLT3 inhibitor in case of FLT3-ITD 17 or hypomethylating agents. 18 In conclusion, despite its retrospective feature, this series allowed to establish a new simplified prognostic score for refractory/relapsed AML patients including three clinical and biological parameters currently routinely applied. Although this was validated here by means of an independent cohort, retrospective and prospective studies are still needed to assess the reproducibility of this new prognostic score for refractory/ relapsed AML patients. 
